European expansion Panaxia has expanded offices into Europe and is actively entering new medical cannabis markets in Europe, presenting sales opportunities for regional distributors, local partners, and regulatory-compliant supply agreements.

EU-GMP production With EU-GMP compliant production and Malta facilities, Panaxia can offer high-quality, standardized cannabis-derived products at scale, enabling partnerships for contract manufacturing and white-label opportunities across Europe.

Clinical partnerships Established collaborations with prominent medical centers and ongoing R&D investments create avenues for joint development deals, clinical trials, and evidence-backed product launches that can drive reimbursement and adoption.

Diverse delivery Offering over 65 products across multiple delivery methods provides breadth for channel partners and clinics seeking customizable cannabis therapies, enabling multi-product sales campaigns and bundled offerings.

Strategic partnerships Recent partnerships, including the Boiron collaboration, suggest a readiness to co-develop and distribute cannabis-based treatments, opening doors for multinational distribution agreements and cross-brand marketing initiatives.